- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04355195
Quality Contract: Prevention of Postoperative Delirium in the Care of Older Patients (QV-POD-2)
Quality Contract Prevention of Postoperative Delirium in the Care of Older Patients (QV-POD-2)
The project "QV-Delirium" is based on the decision of the Federal Joint Committee (G-BA) from 2017. The aim is to improve inpatient care for older patients who are undergoing inpatient surgery and thus to specifically reduce the postoperative risk of delirium. This is achieved through the implementation of evidence-based and consensus-based measures to prevent postoperative delirium in a comprehensive structured concept in routine care. The transparent documentation in an electronic patient file enables the relationships between the symptoms to be depicted in accordance with the clinical circumstances and the genesis of the postoperative delirium to be recorded and treated at an early stage.The independent Institute for Quality Assurance and Transparency in Health Care (IQTIG) receives the elements predefined (e.g. incidence of delirium) by IQTIG with which the quality is measured. The content of the additional elements from the routine data (see primary and secondary outcome measures) is merged internally and with BARMER and other health insurance data for a joint evaluation.
Subproject 1:
Preoperative evaluation of systolic and diastolic heart function in patients of the QV delirium cohort:
In this process, this subproject relates to the evaluation of patients during the premedication visit. During the visit, an evaluation of the heart function using TTE should also take place in order to be able to evaluate later whether there is a association between the preoperative cardiac function examined and the development of postoperative delirium. The parameters to be collected are for the systolic heart function (LVEF, TAPSE, rest LV-SV and SVI, LVCO, LVCI LV / RV index, as well as for the diastolic dysfunction according to current recommendations (Nagueh SF et al., 2016) : MV DecT, MV E / A ratio, E'lat, E'sept, E ', E / E', IVRT-LV, S ', A', LAVI, tricuspid valve flow in tricuspid valve insufficiency: TR V max.
Subproject 2 starts in April 2022:
Anonymous quantitative employee (nurses and doctors) survey on the content of the quality contract with regard to employee satisfaction, feasibility, effectiveness, efficiency (cost-benefit balance), acceptance, needs, quality of the introduction, quality of the implementation.
Study Overview
Status
Conditions
Detailed Description
Study Type
Enrollment (Estimated)
Contacts and Locations
Study Contact
- Name: Claudia Spies, MD, Prof.
- Phone Number: +49 30 450 55 11 02
- Email: claudia.spies@charite.de
Study Locations
-
-
-
Berlin, Germany, 12203
- Recruiting
- Department of Anesthesiology and Intensive Care Medicine (CBF), Charité - Universitätsmedizin Berlin
-
Principal Investigator:
- Sascha Treskatsch, MD, Prof.
-
Contact:
- Sascha Treskatsch, MD. Prof.
- Phone Number: +49 30 450 55 15 22
- Email: sascha.treskatsch@charite.de
-
Sub-Investigator:
- Lennart Junge, MD
-
Berlin, Germany, 13353
- Recruiting
- Department of Anesthesiology and Intensive Care Medicine (CCM/CVK) Berlin, Carité - Universitätsmedizin Berlin
-
Contact:
- Caudia Spies, MD, Pof.
- Phone Number: +49 30 450 55 11 02
- Email: claudia.spies@charite.de
-
Sub-Investigator:
- Fatima Yürek, MD
-
Sub-Investigator:
- Daniel Hadzidiakos, MD
-
Principal Investigator:
- Claudia Spies, MD, Prof.
-
Sub-Investigator:
- Laerson Hoff
-
Sub-Investigator:
- Maurice Breithaupt, MD
-
Sub-Investigator:
- Antje Kirchstein, MD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion criteria:
- Age ≥ 70 years
- male and female patients
- Patients who are insured with BARMER, HEK, KKH, DAK, TK or hkk Health insurances
- Patients eligible for inclusion: by the patient, preoperatively
- Incapacitated patients for inclusion: Written informed consent by a legal representative
- surgery (elective and not elective)
Exclusion criteria:
- Moribund patients
- Not enough language skills
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
Cohorts and Interventions
Group / Cohort |
---|
Cohort before training
500 patients should be asked to participate in the project in the phase of zero value measurement.
The documentation of the routine data before the training phase relates to patients aged ≥70 years, male and female, who are undergoing surgery.
|
Cohort after training 1
From October 1st, 2020, the documentation of the routine data will begin after the training phase: 2,500 patients in 12 months, each aged ≥70 years, male and female, who will have surgery until the end of the contract on June 30th, 2023.
|
Cohort after documentation of routine data until June 2023
From July 1st, 2023, the documentation of the routine data will go on: 1,700 patients in 12 months, each aged ≥70 years, male and female, who will have surgery until the end of the contract on June 30th, 2028.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Delirium
Time Frame: Up to 5 years
|
Decrease in the incidence of delirium and / or shortening of the delirium duration (composite endpoint) taking into account the implementation rates of at least 80% for screening and documentation in the next five years.
|
Up to 5 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Routine laboratory
Time Frame: The participants are followed up until the end of hospital stay, an expected average of 7 days
|
Routine laboratory markers
|
The participants are followed up until the end of hospital stay, an expected average of 7 days
|
Routine vital parameters
Time Frame: The participants are followed up until the end of hospital stay, an expected average of 7 days
|
The participants are followed up until the end of hospital stay, an expected average of 7 days
|
|
Measurement of cholinesterases
Time Frame: The participants are followed up until the end of hospital stay, an expected average of 7 days
|
Cholinesterases (point of care testing (POCT) measurements) are measured in the routine
|
The participants are followed up until the end of hospital stay, an expected average of 7 days
|
Intraoperative routine data
Time Frame: Time of surgery
|
Time of surgery
|
|
Drug administration during inpatient treatment
Time Frame: The participants are followed up until the end of hospital stay, an expected average of 7 days
|
The participants are followed up until the end of hospital stay, an expected average of 7 days
|
|
Routine preventive measures against delirium
Time Frame: The participants are followed up until the end of hospital stay, an expected average of 7 days
|
The participants are followed up until the end of hospital stay, an expected average of 7 days
|
|
Intraoperative documented peculiarities in patients with delirium
Time Frame: Time of surgery
|
Time of surgery
|
|
Anticholinergic drug intake
Time Frame: The participants are followed up until the end of hospital stay, an expected average of 7 days
|
Scale to identify the severity of anticholinergic drugs (Level 0 = no anticholinergic effect, Level 1 = mild anticholinergic effect, Level 2 = moderate anticholinergic effect, Level 3 = severe anticholinergic effect).
The sum of all levels of the different drugs gives the total load.
Higher total loads of anticholinergic drugs are associated with higher anticholinergic drug load.
Minimum of the scale is 0. Maximum depends on the sum of each drug level.
The more drugs with anticholinergic effect are taken the higher is the anticholinergic drug load.
|
The participants are followed up until the end of hospital stay, an expected average of 7 days
|
Incidence of postoperative delirium
Time Frame: The participants are followed up until the end of hospital stay, an expected average of 7 days
|
Incidence of postoperative delirium in all postoperative patients in normal ward, intensive care unit and recovery room after validated delirium screening tool at two points in time (a defined day before the start of the training measures, a defined day after the completion of the training measures).
|
The participants are followed up until the end of hospital stay, an expected average of 7 days
|
Electroencephalography (EEG) measurement
Time Frame: The participants are followed up until the end of hospital stay, an expected average of 7 days
|
Objective non-invasive EEG is measured intraoperatively
|
The participants are followed up until the end of hospital stay, an expected average of 7 days
|
Infections
Time Frame: The participants are followed up until the end of hospital stay, an expected average of 7 days
|
Infections according to surgical site infections (SSI) and according to the US Centers for Disease Control and Preventions (CDC).
|
The participants are followed up until the end of hospital stay, an expected average of 7 days
|
Quality of life 1
Time Frame: Up to three months
|
Health related quality of life is measured by EQ-5D-5L
|
Up to three months
|
Intensive care unit length of stay
Time Frame: Participants will be followed for the duration of intensive care stay, an expected average of 2 days
|
Intensive care unit length of stay is measured in days
|
Participants will be followed for the duration of intensive care stay, an expected average of 2 days
|
Hospital length of stay
Time Frame: The participants are followed up until the end of hospital stay, an expected average of 7 days
|
Hospital length of stay is measured in days
|
The participants are followed up until the end of hospital stay, an expected average of 7 days
|
Care level
Time Frame: Up to one year
|
The care level is taken from hospital records preoperatively and postoperatively
|
Up to one year
|
Postoperative routine data on the ICU, in the recovery room and normal ward
Time Frame: The participants are followed up until the end of hospital stay, an expected average of 7 days
|
The participants are followed up until the end of hospital stay, an expected average of 7 days
|
|
Post Intensive Care Syndrome (PICS)
Time Frame: Up to one year
|
The composite outcome measure "PICS" of the patient is measured according to Needham et al 2012: new impairment or worsening of health after intensive care unit stay and at the same time clinically significant distress in at least one of the following outcome measurement instruments: Patient Health Questionnaires (PHQ-9, PHQ-8, PHQ-4), Generalized Anxiety Disorder Scales (GAD-2 and GAD-7), Impact of Event Scale Revised (IES-R), MiniCog, Animal Naming Test, Trail Making Test (TMT-A, TMT-B), Repeatable Battery for the Assessment of Neuropsychological Satus (RBANS), Timed Up-and-Go (TUG), Handgrip Strength, EQ-5D-5L, subjective assessment NRS, WHO Disability Assessment Schedule (WHODAS), Short Physical Performance Battery (SPPB).
The Measurement will be performed, when patients present to the outpatient clinic for follow-up examinations.
Optionally, the measurement can also be performed via outpatient structures or during a home visit.
|
Up to one year
|
Postoperative complications
Time Frame: The participants are followed up until the end of hospital stay, an expected average of 7 days
|
To evaluate the presence or development of postoperative organ complications during inpatient care
|
The participants are followed up until the end of hospital stay, an expected average of 7 days
|
Pain threshold measurement
Time Frame: During the operation
|
Automatic measurement of specific pain is measured by pain tracker
|
During the operation
|
Analgesia consumption
Time Frame: Up to one year
|
Concomitant pain medication is recorded
|
Up to one year
|
Postoperative cognitive impairment
Time Frame: Up to three months
|
Telephone or Video or questionnaire Follow up is offered to every patient with POD three months and one year after their surgery intervention. The aim of Telephone or Video or questionnaire Follow up is to assess to present Neurocognitive disorder (NCD). The Follow up screening tool is based on DSM 5 diagnostic criteria for "mild cognitive disorder". If one of the diagnostic criteria applies, we recommend to visitvisiting a neuropsychologist/ memory clinic. |
Up to three months
|
Depression
Time Frame: Up to one year
|
Depression is measured by Patient Health Questionnaire-8 (PHQ-8).This scale encompasses eight questions, which can be answered with not at all (0), several days (1), more than half the days (2) and nearly every day (3).
The score is the sum of the 8 items.
The minimum score is 0 (best outcome) and the heights 24 (worse outcome).
|
Up to one year
|
Anxiety
Time Frame: Up to one year
|
Anxiety is measured by Generalized Anxiety Disorder Scale-7 (GAD-7).The Assessment method has seven items; each can be answered with not at all (0), several days (1), more than half the days (2) and nearly every day (3).
The score is the sum of all items.
The minimum and maximum score are 0 (better outcome) and 21 (worse outcome) respectively.
|
Up to one year
|
Physical function
Time Frame: Up to one year
|
Physical health is measured by the sum scores of the following outcome measurement instruments: Timed Up-and-Go (TUG), Handgrip Strength, 2-Minute Walk Test (2-MWT), Short Physical Performance Battery (SPPB).
|
Up to one year
|
Pain levels
Time Frame: Up to one year
|
Pain levels are measured by Numeric Rating Scale - Visualized (NRS-V), which ranges from 0 (no pain) to 10 (extreme pain/ worst pain imaginable).
|
Up to one year
|
Disability 1
Time Frame: Up to one year
|
Disability 1 is measured by Instrumental activities of daily living scale.This scale has 8 categories (ability to use telephone, shopping, food preparation, housekeeping, laundry, mode of transportation, responsibility for own medications, ability to handle finances).
Each has different levels of functioning with a score assigned.
The patient circles the item that most closely describes its functional level.
The lowest score is 0 (better outcome) and the highest is 8 (worse outcome).
|
Up to one year
|
Disability 2
Time Frame: Up to one year
|
Disability 2 is measured by Timed up and go test.
|
Up to one year
|
Disability 3
Time Frame: Up to one year
|
Disability 3 is measured by hand grip strength test
|
Up to one year
|
Anxiety-Score
Time Frame: Up to one year
|
Faces Anxiety Scale score
|
Up to one year
|
Sedation
Time Frame: Up to one year
|
Sedation is measured with the Richmond Agitation and Sedation Scale (RASS)
|
Up to one year
|
Person's level of consciousness
Time Frame: The participants are followed up until the end of hospital stay, an expected average of 7 days
|
The Glasgow Coma Scale (GCS) is a clinical scale used to reliably measure a person's level of consciousness after a brain injury. The GCS assesses a person based on their ability to perform eye movements, speak, and move their body. These three behaviors make up the three elements of the scale: eye, verbal, and motor. A person's GCS score can range from 3 (completely unresponsive) to 15 (responsive). This score is used to guide immediate medical care after a brain injury (such as a car accident) and also to monitor hospitalized patients and track their level of consciousness. Lower GCS scores are correlated with higher risk of death. |
The participants are followed up until the end of hospital stay, an expected average of 7 days
|
Permanent medication
Time Frame: Up to one year
|
Medication at three months compared to baseline is assessed.
|
Up to one year
|
Frailty status
Time Frame: Up to one year
|
Frequency of frailty is measured by modified Fried criteria (category 1 +2 = pre-frail, category 3 -5 = frail)
|
Up to one year
|
Postoperative oral ingestion
Time Frame: The participants are followed up until the end of hospital stay, an expected average of 7 days
|
Ingestion is measured by the amount of fluids and solid food.
|
The participants are followed up until the end of hospital stay, an expected average of 7 days
|
Barthelindex
Time Frame: Up to one year
|
Score of the Barthel Index ranging from 0 to 100 were collected when 0 is the minimum (worst outcome) and 100 is the maximum (best outcome). Score was reported as mean score of the Barthel Index. |
Up to one year
|
Patient-related outcome measures (PROMS)
Time Frame: Up to one year
|
Different tools and questionnaires are combined to measure Patient-related outcome.
|
Up to one year
|
Patient-related experience measures (PREMS)
Time Frame: Up to one year
|
Patient-reported experiences of health care are measured with a questionnaire.
|
Up to one year
|
Therapy recommendations
Time Frame: Up to one year
|
Therapy recommendations are documented from patient records.
|
Up to one year
|
Survival
Time Frame: Up to one year
|
Up to one year
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Preoperative routine data
Time Frame: At baseline
|
Preoperative routine data are medical history, diagnoses, medication, etc.
|
At baseline
|
Patient-specific characteristics
Time Frame: At baseline
|
Patient-specific characteristics of patients with delirium
|
At baseline
|
Preoperative risk score for delirium
Time Frame: At baseline
|
Development of a risk model with different influencing factors of delirium
|
At baseline
|
Heart function
Time Frame: At baseline
|
Heart function is measured by transthoracic echocardiography (TTE)
|
At baseline
|
Preoperative sober times
Time Frame: At baseline
|
At baseline
|
Collaborators and Investigators
Collaborators
Investigators
- Study Director: Claudia Spies, MD, Prof., Charite University, Berlin, Germany
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- QV-POD-2
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Delirium in Old Age
-
University of Modena and Reggio EmiliaUnknownDementia | Cataract | Cataract Senile | Mild Cognitive Impairment | Post-Op Complication | Delirium in Old Age | Delirium Confusional State | Cataract in Old AgeItaly
-
Ain Shams UniversityCompletedDelirium in Old AgeEgypt
-
Aalborg University HospitalCompleted
-
Bnai Zion Medical CenterCompleted
-
Chongqing Traditional Chinese Medicine HospitalNot yet recruiting
-
Chinese PLA General HospitalBeijing Tiantan HospitalRecruiting
-
Brigham and Women's HospitalWithdrawnDelirium in Old AgeUnited States
-
University of ChileCompleted
-
Assiut UniversityNot yet recruitingDelirium in Old Age
-
Duke UniversityMerck Sharp & Dohme LLCRecruitingDelirium in Old AgeUnited States